Central Nervous System

Authorized indications:

Treatment of motor fluctuations (on-off phenomenon) in patients with Parkinson's disease insufficiently controlled by oral antiparkinsonian treatment.

Authorized indications:

LEVENOVA® is indicated as monotherapy in the treatment of partial onset seizures in patients 16 years of age and older with a new epilepsy diagnosis. LEVENOVA® is indicated for concomitant therapy in the treatment of:

• Partial onset seizures in patients 1 month of age and older with epilepsy.
• Myoclonic seizures in patients 12 years of age and older with Juvenile Myoclonic Epilepsy.
• Primary generalized tonic-clonic seizures in patients 12 years of age and older with Idiopathic generalized epilepsy.

Authorized indications:

Adults:

• Olanzapine is indicated for the treatment of schizophrenia.
• Olanzapine is effective in maintaining clinical improvement during continuation therapy in patients who show an initial therapeutic response.
• Olanzapine is indicated for the treatment of moderate to severe manic episode.
• Olanzapine is indicated for the prevention of relapse in patients with bipolar disorder who have responded to treatment with olanzapine during the manic episode.

Authorized indications:

SERTRANOVA® is indicated in the treatment of:

• Major depressive episodes. Prevention of recurrence of major depressive episodes.
• Panic disorder, with or without agoraphobia
• Obsessive-compulsive disorder in adults and pediatric patients aged 6-17 years
• Social anxiety disorder
• Post-traumatic stress disorder

Authorized indications:

Treatment of motor fluctuations (on-off phenomenon) in patients with Parkinson's disease insufficiently controlled by oral antiparkinsonian treatment. French industry.

Authorized indications:

Treatment of major depressive episodes (according to DSM IV). Treatment of panic disorder with or without agoraphobia (according to DSM IV). Treatment of social anxiety disorder (social phobia) (according to DSM IV). Treatment of generalized anxiety disorder (according to DSM IV). Treatment of obsessive-compulsive disorder (according to DSM IV). Portuguese industry

Authorized indications:

DONENOVA® is indicated for the symptomatic treatment of mild to moderately severe Alzheimer's disease.

Portuguese industry

Authorized indications:

• Aripiprazole is indicated for the treatment of schizophrenia (DSM IV) in adults and adolescents aged 15 years and over.
• Aripiprazole is indicated for the treatment of moderate to severe manic episodes in patients with bipolar I disorder (DSM IV) and for the prevention of new manic episodes in adults who have had predominantly manic episodes and who have responded to treatment with aripiprazole.
• Aripiprazole is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder (DSM IV) for up to 12 weeks in adolescents aged 13 years and older.